Loss of ARID1A Protein in Ovarian Clear Cell Carcinoma
Author Information
Author(s): Maeda Daichi, Mao Tsui-Lien, Fukayama Masashi, Nakagawa Shunsuke, Yano Tetsu, Taketani Yuji, Shih Ie-Ming
Primary Institution: Department of Pathology, Graduate School of Medicine, the University of Tokyo
Hypothesis
Does loss of ARID1A protein expression have clinical significance in patients with ovarian clear cell carcinoma?
Conclusion
The study found that loss of ARID1A protein expression is common in ovarian clear cell carcinoma, but it does not correlate with any clinicopathological features or overall survival.
Supporting Evidence
- ARID1A mutations occur in approximately half of ovarian clear cell carcinoma cases.
- ARID1A immunohistochemistry showed concordance with mutational status in 91% of cases.
- Loss of ARID1A expression was observed in 59% of the tumors studied.
- No significant difference in survival was found between ARID1A positive and negative cases.
Takeaway
This study looked at a protein called ARID1A in ovarian cancer. They found that many tumors didn't have this protein, but it didn't seem to affect how patients did overall.
Methodology
Immunohistochemistry was used to evaluate ARID1A expression in 149 cases of ovarian clear cell carcinoma.
Limitations
The study did not find significant correlations between ARID1A expression and various clinicopathological features.
Statistical Information
P-Value
p < 0.05
Statistical Significance
p < 0.0001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website